navigate.sdacreative.net
Open in
urlscan Pro
69.163.219.197
Public Scan
Submitted URL: http://navigate.sdacreative.net/
Effective URL: https://navigate.sdacreative.net/
Submission: On July 07 via api from US — Scanned from DE
Effective URL: https://navigate.sdacreative.net/
Submission: On July 07 via api from US — Scanned from DE
Form analysis 1 forms found in the DOM
GET https://navigate.sdacreative.net/
<form role="search" method="get" class="et-search-form" action="https://navigate.sdacreative.net/">
<input type="search" class="et-search-field" placeholder="Search …" value="" name="s" title="Search for:">
</form>Text Content
sCAUTION – Investigational device. Limited by U.S. Federal law to investigational use under early feasibility study (EFS) and by foreign regulatory agencies for clinical assay in respective countries. * Home * About * Technology * Tricuspid Regurgitation * News & Events * Contact Select Page * Home * About * Technology * Tricuspid Regurgitation * News & Events * Contact ABOUT NAVIGATE CSI Given the unmet clinical need for patients with moderate or greater functional valve regurgitation (FTR)/ tricuspid insufficiency, NCSI is developing a catheter-guided atrioventricular valved stent for replacement of a failing tricuspid valve. Innovative anchoring mechanisms serve to secure and maintain positioning of the replacement valve. Learn More THE TECHNOLOGY The GATE™ System is designed to provide a novel, bio-prosthetic solution for treatment of moderate or greater functional tricuspid regurgitation. Find out more NAVIGATE FAQ'S Tricuspid regurgitation (insufficiency) is a clinical condition that affects millions of people worldwide. While citations in the literature estimated that more than 1.6 million Americans had moderate to severe tricuspid regurgitation in 2006, data presented by key opinion leaders in 2018 estimate that as many as 2.5 million Americans may now be affected. NCSI is developing a solution for heart teams to treat tricuspid regurgitation/insufficiency through valve replacement. Early clinical studies in humans are anticipated to begin in Summer 2019. OUR MISSION The mission of NaviGate Cardiac Structures, Inc., is to be the leader in development of innovative transcatheter bioprosthetic heart valve implants for treating the unmet needs of atrioventricular valve disease. About Us IN THE NEWS IVASCULAR SLU, BARCELONA INVESTS IN NAVIGATE CARDIAC STRUCTURES, INC. At the end of 2018, iVascular SLU, a European medical device company, made an investment in NaviGate Cardiac Structures, Inc. and will be instrumental in helping the company’s developments by providing its expertise in fabrication and manufacturing of various... read more QUEBEC UNIVERSITY IN LAVAL, CANADA. THIS IS THE FIRST TRICUSPID VALVE REPLACEMENT IN CANADA. Communiqué de presse PREMIÈRE MÉDICALE CANADIENNE : UN 10E CAS DE REMPLACEMENT TRICUSPIDE PERCUTANÉ AU MONDE RÉALISÉ À L’INSTITUT Québec, 8 février 2018 – L’Institut universitaire de cardiologie et de pneumologie de Québec– Université Laval (l’Institut) a récemment... read more NAVIGATE CARDIAC STRUCTURES, INC., PRESENTS DATA OF STUDIES ON THE GATE™ VALVED STENT FOR CORRECTION OF FUNCTIONAL TRICUSPID REGURGITATION AT PARIS PCR2016. Jose L Navia, M.D., from Cleveland Clinic presented the summary of animal studies of the Gate™valved stent for catheter-guided orthotopic implantation procedure for the correction of Functional Tricuspid Regurgitation (FTR). Functional tricuspid regurgitation occurs... read more Tricuspid Regurgitation, TR, FTR, Valve Replacement, Novel Solution, Unmet Clinical Need, Ignored Valve, Forgotten Valve BROWSE * Home * About * Technology * Tricuspid Regurgitation * News & Events * Investors * Contact HAVE QUESTIONS? Do you have questions about the NaviGate™ System? Please let us know! Send us an email © 2019 NaviGate Cardiac Structures, Inc. - All Rights Reserved. Terms and Conditions | Privacy Policy | Website and Design by SDA Creative